Adverse Event Disclosure Standards Could Be Altered By Supreme Court In Matrixx Case
Executive Summary
Supreme Court justices appeared skeptical of Matrixx Initiatives’ insistence that companies need not tell investors about reports of drug adverse events unless they are statistically significant, suggesting the court may set a different disclosure standard for a securities fraud suit.
You may also be interested in...
Adverse Events Disclosures May Increase After Supreme Court Ruling Against Matrixx, But "Total Mix" Matters
Companies may have to disclose adverse event reports that are not statistically significant, but the court says the amount of disclosure needed can be limited by how much a company tells the market about an issue in general.
Supreme Court To Consider What Adverse Events Pharma Must Report To Avoid Securities Suits
The court will decide whether companies can be sued for failing to disclose adverse event reports that are not statistically significant; the case before the court involves Matrixx's Zicam Cold Remedy products.
Supreme Court Lets Vioxx Securities Suit Against Merck Stand
The top U.S. court clarifies when the statute of limitations for filing suit begins to run and specifies that intent to deceive is crucial in determining if a violation occurred.